Table 3:
Estimated lifetime number of diagnosed cases of health outcomes attributable to HPV infections acquired in 2018, discounted cost per case, and total discounted lifetime costs attributable to HPV infections acquired in 2018
| Health outcome | Lifetime number of diagnosed cases attributable to HPV infections acquired in 2018 |
Average discounted cost per health outcome | Total discounted lifetime cost of health outcomes attributable to HPV infections acquired in 2018 |
||
|---|---|---|---|---|---|
| Ages 15–59 years | Ages 15–24 years | Ages 15–59 years | Ages 15–24 years | ||
| Genital warts, females | 25,442 | 6,310 | $860 | $21,880,000 | $5,427,000 |
| Genital warts, males | 24,967 | 2,325 | $860 | $21,472,000 | $2,000,000 |
| CIN grade 1 | 162,974 | 103,660 | $1,370 | $223,274,000 | $142,014,000 |
| CIN grade 2 or 3 | 52,074 | 29,707 | $2,380 | $123,936,000 | $70,703,000 |
| Penile cancer | 454 | 265 | $17,100 | $7,763,000 | $4,532,000 |
| Cervical cancer | 3,153 | 1,978 | $34,300 | $108,148,000 | $67,845,000 |
| Vulvar & vaginal cancer | 849 | 550 | $23,200 | $19,697,000 | $12,760,000 |
| Anal cancer, females | 780 | 441 | $30,000 | $23,400,000 | $13,230,000 |
| Anal cancer, males | 675 | 268 | $32,800 | $22,140,000 | $8,790,000 |
| Oropharyngeal cancer, females | 587 | 370 | $39,400 | $23,128,000 | $14,578,000 |
| Oropharyngeal cancer, males | 3,665 | 1,462 | $41,800 | $153,197,000 | $61,112,000 |
| RRP | NA* | NA* | NA | $26,011,000 | $4,456,000 |
| All outcomes, females | 245,859 | 143,016 | NA | $543,463,000 | $326,557,000 |
| All outcomes, males | 29,761 | 4,320 | NA | $204,572,000 | $76,434,000 |
| All outcomes, total | 275,620 | 147,336 | NA | $774,046,000 | $407,447,000 |
CIN: cervical intraepithelial neoplasia. RRP: recurrent respiratory papillomatosis. NA: not applicable.
The age groupings refer to age at the time of the causal HPV infection (2018), not the age at which the health outcome was diagnosed.
Costs are in 2019 U.S. dollars. Future costs for each outcome were discounted at an annual rate of 3%. Total costs were rounded to the nearest $1,000.
RRP was not included in the HPV-ADVISE model. Costs for RRP included juvenile-onset RRP and adult-onset RRP and were estimated as a fraction (60%) of the costs of genital warts as described in the text.